|  |  |
| --- | --- |
| Current age-months (median/min-max) | 112.5/3.6-294 |
| Age at the first application-months (median/min-max) |  45/1.2-204.7 |
| Sex (male, n/%) | 25/62.5 |
| Consanguineous marriage (n/%) | 18/45 |
| History of stroke in their relatives (n/%) | 6/15 |
| Patients according to risk factors | (n/%) |
|  a-Prothrombotic reasons  | 27/67.5 |
|  b-Congenital heart diseases  | 26/65 |
|  c-Infections  | 13/32.5 |
|  d-Hematologic reasons  | 12/30 |
|  e-Arteriopathies/rheumatologic diseases  | 5/12.5 |
|  f-Genetic diseases  | 3/7.5 |
|  g-Metabolic diseases  | 1/2.5 |
|  h-More than one risk factor  | 34/85 |
| The first presentation clinic | (n/%) |
|  a-Seizure  | 17/42.5 |
|  b-Motor deficit/weakness  |  10/25 |
|  c-Emotional deficit  |  1/2.5 |
|  d-Change in consciousness  |  3/7.5 |
|  e-Headache  |  1/2.5 |
|  f-Ataxy  |  2/5 |
|  g-Chorea |  2/5 |
|  h-Ocular motility disorder  |  2/5 |
|  I-Diplopia  |  2/5 |
| Treatment | Start (n/%) | Continuation (n/%) |
|  a-Heparin  | 5/12.5 |  |
|  b-Lmwh (Low molecular weight heparin) | 20/50 | 21/52.5 |
|  c-Aspirin  | 8/20 | 12/30 |
|  d-Warfarin  | 1/2.5 |  |
|  e-Others | 6/15 | 7/17.5 |
|  | n/% |
| Aphasia  | 1/2.5 |
| Hemiplegia  | 16/40 |
| Development of epilepsy  | 24/60 |
| Recurrence  | 3/7.5 |
| Acute/Long-term mortality  | 6/15 | 13/32.5 |

**Table-1: Patients’ demographic and clinic qualities**

|  |
| --- |
| A-Barthel Functionality Scale |
|  | n/% |  |
| Fully independent  | 8/20 | Positive prognosis |
| Lowly dependent  | 1/2.5 | Prognosis not positive |
| Moderately dependent  | 9/22.5 |
| Highly dependent  | 7/17.5 |
| Fully dependent  | 2/5 |
|  | Average ± standard deviation |
| Barthel score | 68.0 ± 28.9 |
| B-WeeFIM Functionality Scale |
|  | Average ± standard deviation |
| Motor | 66.0±23.3 |
| Cognitive | 28.6±8.4 |
| Total  | 94.5±29.8 |
| Self-care | 28.2±11.5 |
| Sphincter control | 11.2±3.6 |
| Transfers | 16.0±5.8 |
| Action  | 10.6±4.0 |
| Communication | 11.7±3.4 |
| Social status | 16.9±5.1 |
| C-SF36 Life Quality Scale |
|  | Average ± standard deviation |  |
| Physical function | 49.1±39.1 |  |
| Physical role difficulty | 37.5±48.6 |  |
| Pain | 83.6±27.5 | The highest |
| General health perception | 38.6±19.7 |  |
| Energy vitality | 43.6±17.6 |  |
| Social functionality | 63.1±31.5 |  |
| Emotional role difficulty | 36.4±49.2 | The lowest |
| Psychological health | 53.3±10.9 |  |
| D-Motor Outcomes with GMFCS |
|  | n/% |  |
| 1 | 8/20 | Positive  |
| 2 | 12/30 | Not positive |
| 3 | 2/5 |
| 4 | 3/7.5 |
| 5 | 2/5 |

**Table-2: Our patients’ functionalities, life qualities and motor outcomes in prognostic terms**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | Mortality group | Survival group | P |
| Age range of 2-5  | % | 46.2 | 3.7 | <0.001 |
| Consanguineous marriage  | 76.9 | 29.6 | 0.005 |
| Presence of VSD  | 38.5 | 7.4 | 0.027 |
| Presence of cardiomyopathy  | 23.1 | 0 | 0.029 |
| Valvular heart disease  | 69.2 | 29.6 | 0.018 |
| Presence of lupus anticoagulant | 30.8 | 11.1 | 0.019 |
| Raised AST  | 53.8 | 22.2 | 0.043 |
| Raised ALT  | 30.8 | 0 | 0.010 |
| Na abnormality  | 53.8 | 11.1 | 0.011 |
| Hypocalcaemia  | 23.1 | 0 | 0.029 |
| Raised CRP  | 76.9 | 33.3 | 0.034 |
| Follow-up period <6 months  | 69.2 | 3.7 | 0.001 |
| Leucocyte  | Count (n/mm3, mean) | 15313+6289 | 10075+2916 | 0.012 |
| ANS  | 10006+5716 | 5865+3125 | 0.022 |
| PLT  | 269153±231469 | 337666±128101 | 0.039 |
| Pyruvate  | (mg/l, mean) | 3.7+0.2 | 1.0+0.6 | 0.031 |
| D-dimer  | (ng/ml, mean) | 5835.1±8575.5 | 870.4±1103.0 | 0.004 |

**Table-3: Statistically significant factors affecting the long-term mortality-1**

|  |  |  |
| --- | --- | --- |
|   | Univariate | Multivariate |
| OR (%95CI) | P | OR (%95CI) | P |
| Age range (1 month-2 years) |  |  |  |  |
| 2-5 years | 2 (0.09–44.35) | 0.661 |  |  |
| >5 years | 0.053 (0.004–0.648) | **0.021** |  |  |
| Consanguinity (no) | 7.917 (1.711–36.633) | **0.008** |  |  |
| VSD (no) | 7.812 (1.262–48.356) | **0.027** |  |  |
| Valvular heart disease (no) | 5.344 (1.268–22.523) | **0.022** | 268.204 (1.21–59441.503) | **0.042** |
| Na level (normal) | 8 (1.537–41.637) | **0.013** |  |  |
| CRP level (normal) | 6.296 (1.374–28.855) | **0.018** |  |  |
|  |  |  |  |  |
| Follow-up period (<6 months) |  |  |  |  |
| 6-12 months | 0.016 (0.001–0.301) | **0.006** |  |  |
| 12-24 months | 0.056 (0.002–1.319) | 0.074 |  |  |
| >24 months | 0.013 (0.001–0.165) | **0.001** |  |  |
| AST | 1.025 (0.999–1.053) | 0.059 |  |  |
| ALT | 1.05 (0.994–1.111) | 0.083 |  |  |
| Na | 1.037 (0.888–1.21) | 0.648 |  |  |
| CRP | 1.091 (0.993–1.198) | 0.07 |  |  |
| Follow-up period | 0.929 (0.876–0.986) | **0.016** | 0.906 (0.824–0.997) | **0.043** |
| Ca | 0.104 (0.021–0.513) | **0.005** |  |  |
| Wbc | 1.0003 (1.00007–1.0005) | **0.007** | 1.001 (1–1.001) | **0.034** |

\* (reference category), Backward: Wald model was used in including the independent risk factors in multivariate model.

**Table-4: Factors affecting the long-term mortality-2**